Abstract:

Objective To investigate the safety and efficacy of prophylactic anticoagulant therapy in patients with heart failure in sinus rhythm. Methods The related research of anticoagulant therapy for patients with heart failure in sinus rhythm were collected from Pubmed, Embass, Cochrane databases for a Meta-analysis, the deadline was until June 1, 2021. The safety and efficacy of anticoagulant drugs preventing heart failure in sinus rhythm were assessed. Results Eligible 9 studies were included. Meta-analysis confirmed the difference was not statistically significant in the all-cause mortality rate (OR=0.87, 95%CI: 0.75-1.01, P=0.08), myocardial infarction rate (OR=0.86, 95%CI: 0.71-1.04, P=0.12), related readmission rate (OR=0.90, 95%CI: 0.75-1.07, P=0.23) between anticoagulant therapy and non-anticoagulant therapy. Compared with non-anticoagulant therapy, anticoagulant therapy could significantly reduce the risk of ischemic stroke (OR=0.38, 95%CI: 0.16-0.93, P=0.03), but meantime, increase the bleeding risk (OR=1.69, 95%CI: 1.43-2.00, P<0.05). Conclusion Anticoagulant therapy can effectively reduce stroke risk for patients with heart failure in sinus rhythm. Although the all-cause mortality rate and myocardial infarction rate of these patients tend to decrease, bleeding risk should be attention.

Key words: heart failure, sinus rhythm, anticoagulants, platelet aggregation inhibitors